ReviewGerman medical science : GMS e-journal2017
Cannabinoid hyperemesis and the cyclic vomiting syndrome in adults: recognition, diagnosis, acute and long-term treatment.
Review in German medical science : GMS e-journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- European Guideline on Chronic Nausea and Vomiting-A UEG and ESNM Consensus for Clinical Management.United European gastroenterology journal · 2025Guideline
- Cannabis Use Patterns and Whole-Blood Cannabinoid Profiles of Emergency Department Patients With Suspected Cannabinoid Hyperemesis Syndrome.Annals of emergency medicine · 2023Observational
- An analysis of cannabinoid hyperemesis syndrome Reddit posts and themes.Clinical toxicology (Philadelphia, Pa.) · 2023Article
- Considering Cannabis Use in Differential Diagnosis: A Teachable Moment.JAMA internal medicine · 2022Article
- Cannabis-Related Cyclic/Episodic Hyperemesis Conditions: From Suspected to Definitive Cannabinoid Hyperemesis Syndrome.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2022Article
- Reply to Letter "Cannabis-Related Cyclic/Episodic Hyperemesis Conditions: From Suspected to Definitive Cannabinoid Hyperemesis Syndrome".Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2022Article
- Treatment of Cyclic Vomiting Syndrome: Is Bathing a Panacea or Is It in Hot Water?Digestive diseases and sciences · 2021Article
- Marijuana: A systems-based primer of adverse effects associated with use and an overview of its therapeutic utility.SAGE open medicine · 2021Review
- Intravenous haloperidol for the treatment of intractable vomiting, cyclical vomiting, and gastroparesis.World journal of emergency medicine · 2021Article
- Role of the stress response and the endocannabinoid system in ΔPsychopharmacology · 2020Article
- Cannabinoid Hyperemesis Syndrome: A Review of Potential Mechanisms.Cannabis and cannabinoid research · 2020Review
- Prevalence of cannabis use has significantly increased in patients with cyclic vomiting syndrome.Neurogastroenterology and motility · 2020Article
- Cannabinoid Hyperemesis Syndrome: A Case Report and Discussion Regarding Patients with Concurrent Disorders.The Canadian journal of hospital pharmacy · 2020Article
- Cannabinoid Hyperemesis.Medical cannabis and cannabinoids · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cannabinoid hyperemesis syndrome (CHS) and the cyclic vomiting syndrome in adults (CVS) are both characterized by recurrent episodes of heavy nausea, vomiting and frequently abdominal pain. Both syndromes are barely known among physicians. Literature is inconsistent concerning clinical features which enable differentiation between CVS and CHS. We performed a literature review using the LIVIVO search portal for life sciences to develop a pragmatic approach towards these two syndromes. Our findings indicate that complete and persistent resolution of all symptoms of the disease following cannabis cessation is the only reliable criterion applicable to distinguish CHS from CVS. Psychiatric comorbidities (e.g. panic attacks, depression), history of migraine attacks and rapid gastric emptying may serve as supportive criteria for the diagnosis of CVS. Compulsive bathing behaviour, a clinical observation previously attributed only to CHS patients is equally present in CVS patients. Long-term follow-up is essential in order to clearly separate CHS from CVS. However, long-term follow-up of CVS and CHS cases is seldom. We provide a standard operating procedure applicable to a broad spectrum of health care facilities which addresses the major issues of CVS and CHS: awareness, diagnosis, treatment, and follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.